<DOC>
	<DOCNO>NCT01529164</DOCNO>
	<brief_summary>Studies suggest addition antiangiogenic agent conventional therapeutic strategy , e.g. , chemotherapy , radiation , tumor-targeting agent , increase clinical efficacy . For advanced colorectal cancer , antiangiogenic agent bevacizumab become important treatment option combination chemotherapy one standard first line therapy . This phase II study conduct determine efficacy safety another antiangiogenesis inhibitor rh-endostatin plus mFOLFOX6 advanced colorectal cancer .</brief_summary>
	<brief_title>Efficacy Safety Study Recombinant Endostatin Combined With Chemotherapy Treat Advanced Colorectal Cancer</brief_title>
	<detailed_description>Rh-Endostatin ( Endostar ; Simcere Pharmaceutical Co. , Ltd , JiangSu , China ) humanize recombinant endostatin direct angiogenesis inhibitor target microvascular endothelial cell ( ECs ) . A pivotal phase III study complete China demonstrate addition rh-endostatin navelbine plus cisplatin confer clinically significant improvement overall survival ( OS ) , progression-free survival ( PFS ) , well response rate ( RR ) , patient previously untreated metastatic non small cell lung cancer ( NSCLC ) . In vitro , combination Endostatin fluorouracil show synergistic activity inhibit colon cancer . MFolfox6 standard first-line regimen advance colorectal cancer . The investigator carry phase II trial investigate activity safety rh-endostatin plus mFOLFOX patient metastatic colorectal cancer .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Signed informed consent ( IC ) Age great equal 18 year Histologically cytologically confirm metastatic recurrent colorectal tumor previous treatment advance disease . At least one measurable lesion accord RECIST criterion irradiate ( i.e . newly arise lesion previously irradiate area accept ) . Minimum indicator lesion size : &gt; 10 mm measure spiral CT &gt; 20mm measure conventional technique ECOG performance status 01 Life expectancy &gt; 3 month ECG normal Pregnant lactate woman Any prior oxaliplatin treatment , exception adjuvant therapy give &gt; 12 month prior begin study therapy , prior 5Ôºçfluorouracil treatment , exception adjuvant therapy give &gt; 6 month prior begin study therapy Any prior endostatin treatment know hypersensitivity 5fluorouracil , oxaliplatin , leucovorin History persistent neurosensory disorder include limited peripheral neuropathy know DPD deficiency Treatment carcinoma within last five year , except cure nonmelanoma skin treat insitu cervical cancer Clinically significant cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) within last 6 month Any follow laboratory value : Abnormal hematologic value ( neutrophil &lt; 1.5 x 109/L , platelet count &lt; 100 x 109/L ) Urine protein : creatinine ratio &gt; /= 1.0 , Impaired renal function estimate creatinine clearance &lt; 30 ml/min Serum bilirubin &gt; 1.5 x upper normal limit . ALT , AST &gt; 2.5 x upper normal limit ( &gt; 5 x upper normal limit case liver metastasis ) Alkaline phosphatase &gt; 2.5 x upper normal limit ( &gt; 5 x upper normal limit case liver metastases &gt; 10 x upper normal limit case bone disease ) use fulldose anticoagulant thrombolytic know CNS metastases serious nonhealing wound , ulcer , bone fracture clinically significant bleed diathesis coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>endostatin</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>antiangiogenesis agent</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>